Anthony Sheehan, CEO at Saneca Pharma

Anthony Sheehan, CEO at Saneca Pharma

Slovakia-based contract development and manufacturing organization (CDMO) Saneca Pharma has sold registration dossiers for more than 20 pharmaceutical products to Switzerland-headquartered Xantis Pharma as part of an exclusive agreement.

The portfolio of products will be marketed by Xantis Pharma throughout Central and Eastern Europe, where the company has a growing presence. As part of the collaboration, the European CDMO will hold an exclusive 5-year contract manufacturing agreement for the products with Xantis Pharma.

Saneca Pharma will continue to act as Xantis Pharma’s agent for out-licensing opportunities for the dossiers outside of these regions.

Anthony Sheehan, CEO at Saneca Pharma said: “We have an established relationship with Xantis Pharma for manufacturing pharmaceutical products based on Xantis’s own registration dossiers. With the purchase of Saneca Pharma’s dossiers, the relationship has now evolved to another level, so we are looking forward to working together to expand the reach of these products in Europe. The partnership combines Xantis Pharma’s market knowledge and access to central and eastern Europe markets with Saneca Pharma’s technical agility and cost-effective development and manufacturing expertise. In the coming months, we expect to see more rapid growth of existing product lines and speedier market entry for those in our pipeline.”

Grigory Chudakov, Chief Commercial Officer at Xantis Pharma, said: “By combining our strong market presence in Central and Eastern Europe with Saneca Pharma’s strengths in drug development and manufacturing, we are confident that we can expand the reach of the 20 pharmaceutical products that have transferred to our portfolio. Our companies are well aligned in terms of strengths and goals and we look forward to a successful partnership for many years.”

The two firms have also committed to working together to develop nine new products in the next 3 years. While Saneca Pharma will use its expertise in formulation development and regulatory support, Xantis Pharma will promote the new offerings to the market.